Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACE: Palbociclib After CDK and Endocrine Therapy in ER+/HER2- Metastatic Breast Cancer
NCT03147287Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2017
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib, avelumab in breast cancer, sponsored by Dana-Farber Cancer Institute. Started Sep 2017; status: active, not recruiting.
02
Drugs
palbociclibavelumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03147287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03147287.